Patents by Inventor Vodek Sasak
Vodek Sasak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160346317Abstract: The present invention is directed to methods and compositions for augmenting treatment of cancers and other proliferative disorders. In particular embodiments, the invention combines the administration of an agent that inhibits the anti-apoptotic activity of galectin-3 (e.g., a “galectin-3 inhibitor”) so as to potentiate the toxicity of a chemotherapeutic agent. In certain preferred embodiments, the conjoint therapies of the present invention can be used to improve the efficacy of those chemotherapeutic agents whose cytotoxicity is influenced by the status of an anti-apoptotic Bcl-2 protein for the treated cell. For instance, galectin-3 inhibitors can be administered in combination with a chemotherapeutic agent that interferes with DNA replication fidelity or cell-cycle progression of cells undergoing unwanted proliferation.Type: ApplicationFiled: February 26, 2016Publication date: December 1, 2016Inventors: Yan Chang, Vodek Sasak
-
Publication number: 20150133399Abstract: The present invention is directed to methods and compositions for augmenting treatment of cancers and other proliferative disorders. In particular embodiments, the invention combines the administration of an agent that inhibits the anti-apoptotic activity of galectin-3 (e.g., a “galectin-3 inhibitor”) so as to potentiate the toxicity of a chemotherapeutic agent. In certain preferred embodiments, the conjoint therapies of the present invention can be used to improve the efficacy of those chemotherapeutic agents whose cytotoxicity is influenced by the status of an anti-apoptotic Bcl-2 protein for the treated cell. For instance, galectin-3 inhibitors can be administered in combination with a chemotherapeutic agent that interferes with DNA replication fidelity or cell-cycle progression of cells undergoing unwanted proliferation.Type: ApplicationFiled: December 18, 2014Publication date: May 14, 2015Inventors: Yan Chang, Vodek Sasak
-
Publication number: 20140148404Abstract: The present invention is directed to methods and compositions for augmenting treatment of cancers and other proliferative disorders. In particular embodiments, the invention combines the administration of an agent that inhibits the anti-apoptotic activity of galectin-3 (e.g., a “galectin-3 inhibitor”) so as to potentiate the toxicity of a chemotherapeutic agent. In certain preferred embodiments, the conjoint therapies of the present invention can be used to improve the efficacy of those chemotherapeutic agents whose cytotoxicity is influenced by the status of an anti-apoptotic Bcl-2 protein for the treated cell. For instance, galectin-3 inhibitors can be administered in combination with a chemotherapeutic agent that interferes with DNA replication fidelity or cell-cycle progression of cells undergoing unwanted proliferation.Type: ApplicationFiled: January 29, 2014Publication date: May 29, 2014Applicant: LA JOLLA PHARMACEUTICAL COMPANYInventors: Yan Chang, Vodek Sasak
-
Publication number: 20080089959Abstract: The present invention is directed to methods and compositions for augmenting treatment of cancers and other proliferative disorders. In particular embodiments, the invention combines the administration of an agent that inhibits the anti-apoptotic activity of galectin-3 (e.g., a “galectin-3 inhibitor”) so as to potentiate the toxicity of a chemotherapeutic agent. In certain preferred embodiments, the conjoint therapies of the present invention can be used to improve the efficacy of those chemotherapeutic agents whose cytotoxicity is influenced by the status of an anti-apoptotic Bcl-2 protein for the treated cell. For instance, galectin-3 inhibitors can be administered in combination with a chemotherapeutic agent that interferes with DNA replication fidelity or cell-cycle progression of cells undergoing unwanted proliferation.Type: ApplicationFiled: May 11, 2007Publication date: April 17, 2008Applicant: Prospect Therapeutics, Inc.Inventors: Yan Chang, Vodek Sasak
-
Patent number: 6890906Abstract: Disease conditions which are dependent upon or moderated by angiogenesis are controlled by the use of a therapeutic material which interacts with cell surface galectins. Particular therapeutic materials comprise a polymeric backbone having side chains terminating in a sugar dependent therefrom. Disclosed are specific therapeutic materials in which the polymeric backbone is based upon polygalacturonic acid, and the side chains terminate in arabinose or galactose.Type: GrantFiled: November 19, 2002Date of Patent: May 10, 2005Assignee: Glycogenesys, Inc.Inventors: Yan Chang, Vodek Sasak
-
Publication number: 20040223971Abstract: The present invention is directed to methods and compositions for augmenting treatment of cancers and other proliferative disorders. In particular embodiments, the invention combines the administration of an agent that inhibits the anti-apoptotic activity of galectin-3 (e.g., a “galectin-3 inhibitor”) so as to potentiate the toxicity of a chemotherapeutic agent. In certain preferred embodiments, the conjoint therapies of the present invention can be used to improve the efficacy of those chemotherapeutic agents whose cytotoxicity is influenced by the status of an anti-apoptotic Bcl-2 protein for the treated cell. For instance, galectin-3 inhibitors can be administered in combination with a chemotherapeutic agent that interferes with DNA replication fidelity or cell-cycle progression of cells undergoing unwanted proliferation.Type: ApplicationFiled: April 7, 2004Publication date: November 11, 2004Applicant: GlycoGenesys, Inc.Inventors: Yan Chang, Vodek Sasak
-
Publication number: 20040121981Abstract: Disease conditions which are dependent upon or moderated by angiogenesis are controlled by the use of a therapeutic material which interacts with cell surface galectins. Particular therapeutic materials comprise a polymeric backbone having side chains terminating in a sugar dependent therefrom. Disclosed are specific therapeutic materials in which the polymeric backbone is based upon polygalacturonic acid, and the side chains terminate in arabinose or galactose.Type: ApplicationFiled: September 16, 2003Publication date: June 24, 2004Applicant: GlycoGenesys, Inc.Inventors: Yan Chang, Vodek Sasak
-
Publication number: 20040043962Abstract: The efficacy of conventional cancer therapies such as surgery, chemotherapy and radiation is enhanced by the use of a therapeutic material which binds to and interacts with galectins. The therapeutic material can enhance apoptosis thereby increasing the effectiveness of oncolytic agents. It can also inhibit angiogenesis thereby moderating tumor growth and/or metastasis.Type: ApplicationFiled: September 8, 2003Publication date: March 4, 2004Applicant: GlycoGenesys, Inc.Inventors: Yan Chang, Vodek Sasak
-
Publication number: 20040023925Abstract: The efficacy of conventional cancer therapies such as surgery, chemotherapy and radiation is enhanced by the use of a therapeutic material which binds to and interacts with galectins. The therapeutic material can enhance apoptosis thereby increasing the effectiveness of oncolytic agents. It can also inhibit angiogenesis thereby moderating tumor growth and/or metastasis.Type: ApplicationFiled: April 7, 2003Publication date: February 5, 2004Inventors: Yan Chang, Vodek Sasak
-
Patent number: 6680306Abstract: The efficacy of conventional cancer therapies such as surgery, chemotherapy and radiation is enhanced by the use of a therapeutic material which binds to and interacts with galectins. The therapeutic material can enhance apoptosis thereby increasing the effectiveness of oncolytic agents. It can also inhibit angiogenesis thereby moderating tumor growth and/or metastasis.Type: GrantFiled: June 20, 2002Date of Patent: January 20, 2004Assignee: GlycoGenesys, Inc.Inventors: Yan Chang, Vodek Sasak
-
Publication number: 20030100535Abstract: Disease conditions which are dependent upon or moderated by angiogenesis are controlled by the use of a therapeutic material which interacts with cell surface galectins. Particular therapeutic materials comprise a polymeric backbone having side chains terminating in a sugar dependent therefrom. Disclosed are specific therapeutic materials in which the polymeric backbone is based upon polygalacturonic acid, and the side chains terminate in arabinose or galactose.Type: ApplicationFiled: November 19, 2002Publication date: May 29, 2003Inventors: Yan Chang, Vodek Sasak
-
Publication number: 20030013681Abstract: The efficacy of conventional cancer therapies such as surgery, chemotherapy and radiation is enhanced by the use of a therapeutic material which binds to and interacts with galectins. The therapeutic material can enhance apoptosis thereby increasing the effectiveness of oncolytic agents. It can also inhibit angiogenesis thereby moderating tumor growth and/or metastasis.Type: ApplicationFiled: June 20, 2002Publication date: January 16, 2003Inventors: Yan Chang, Vodek Sasak
-
Publication number: 20030004132Abstract: An immune response in an organism is controlled by administering to said organism a therapeutically effective amount of a compound which binds to a galectin. In specific instances the compound is selected to bind to galectin-1 or galectin-3. Some therapeutic materials comprise natural or synthetic polymers having galactose or arabinose terminated side chains pendent therefrom. A group of preferred therapeutic compounds comprise modified pectins or other materials having a substantially demethoxylated rhamnogalacturan backbone having rhamnose residues interrupting the backbone. One therapeutic material includes a first functional portion which binds to the carbohydrate binding portion of a galectin, and a second functional portion which is operable to denature the galectin protein.Type: ApplicationFiled: June 20, 2002Publication date: January 2, 2003Inventors: Yan Chang, Vodek Sasak